Background Immune checkpoint inhibitors (ICIs) such as PD (L) 1 and CTLA4 antibodies as
well as targeted therapies such as BRAF and MEK inhibitors have significantly improved the …

Simple Summary Cutaneous side effects are among the most frequently reported adverse
reactions of modern dermato-oncological therapies, such as immune checkpoint inhibitors …

Immune checkpoint inhibitors (ICIs) are a relatively novel class of drugs whose
administration has been approved for several malignancies. Adverse events are quite …

Immune system escape is one of the major strategies required for cancer growths. In this
scenario, the advent of immune checkpoint inhibitors (ICIs) revolutionized the landscape of …

The management of oncology patients has been deeply modified over recent years by the
development of new targeted anticancer therapies. Though these new therapies generally …

Chemotherapeutic agents and drugs used for targeted tumor therapy often cause
undesirable side effects of the skin which typically are toxic cutaneous reactions (toxicity …

The introduction of immune checkpoint inhibitors (ICIs) opened a new era in oncologic
therapy. The favourable profile of ICIs in terms of efficacy and safety can be overshadowed …

In 2021 an estimated 229,200 Canadians were diagnosed with cancer. 1 In Canada, of the
four most commonly diagnosed types of cancer (lung, breast, colorectal, and prostate) …

Immune checkpoint inhibitors (ICIs) have significantly advanced the treatment of cancer.
They are not, however, free of adverse effects. These effects are called immune-related …

The development of immune checkpoint inhibitors (monoclonal antibodies targeting PD-
1/PD-L1 or CTLA-4) represents a significant advance in the treatment of multiple cancers …